BACKGROUND: Concern and controversy characterize nowadays the use of hormone therapy for management of patients with menopausal complaints. This observational non-interventional study examined the use of a marketed oral formulation containi…
ObjectiveTo examine the conception rate after cessation of a combination of 30 microg ethinyl E2 and 2 mg dienogest (EE/DNG).DesignProspective observational study.SettingPopulation-based cohort in Germany.Patient(s)Women who wished to becom…
Fragestellung: Retrospektiven Untersuchungen haben gezeigt, dass die Fertilität nach dem Absetzen eines oralen Kontrazeptivums (OC) für die Dauer von bis zu 2 Jahren negativ beeinflusst werden kann. Bei repräsentativen Umfragen nahmen in Dr…
The effects of Valette--an oral contraceptive containing ethinyloestradiol 0.03 mg and the antiandrogenic progestogen dienogest 2.0 mg--on the skin and hair were surveyed over 63,474 cycles in 10,718 women in routine gynaecological practice…
SUMMARY The effects of Valette ® ‐ an oral contraceptive containing ethinyloestradiol 0.03 mg and the antiandrogenic progestogen dienogest 2.0 mg ‐ on the skin and hair were surveyed over 63,474 cycles in 10,718 women in routine gynaecologi…
Objectives and methods A postmarketing survey was carried out to determine the efficacy and tolerability of Valette® (dienogest 2.0 mg and ethinylestradiol 0.03 mg) in routine gynecological practice.Results Valette had excellent contracepti…
OBJECTIVES AND METHODS: A postmarketing survey was carried out to determine the efficacy and tolerability of Valette (dienogest 2.0 mg and ethinylestradiol 0.03 mg) in routine gynecological practice. RESULTS: Valette had excellent contracep…